MeiraGTx Holdings plc
As of Oct 22, 2026, MeiraGTx Holdings is in Stage 3, the topping phase, now in week 4 (since Sep 30, 2026). It closed at $9.77, 34.7% below its 52-week high and below its 200-day average, which is rising.
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MGTX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MGTX among Biotechnology169th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …169 | MGTX | Stage 3 · wk 4 | 59 | −16.9% |
MeiraGTx Holdings: quick answers
What stage is MeiraGTx Holdings in?
As of Oct 22, 2026, MeiraGTx Holdings (MGTX) is in Stage 3, the topping phase. It entered Stage 3 on Sep 30, 2026 and is in week 4. What the four stages mean
Is MeiraGTx Holdings in an uptrend?
Its uptrend has stalled. MeiraGTx Holdings is in Stage 3, the topping phase that follows an advance. It trades 4.7% below its 200-day average, which is rising.
How far is MeiraGTx Holdings from its 52-week high?
MeiraGTx Holdings closed at $9.77 on Oct 22, 2026, 34.7% below its 52-week high of $14.97. Its 52-week low is $6.99.
How has MeiraGTx Holdings performed over the past year?
As of Oct 22, 2026, MeiraGTx Holdings is up 5.5% over the past year and up 25.1% so far in 2026.
Which sector and industry is MeiraGTx Holdings in?
MeiraGTx Holdings is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.